P133-OA: Combined targeting of chemoresistant cancer cells and immune-suppressive CAFs for cancer therapy
FAU own research funding: EFI / IZKF / EAM ...
Start date : 01.01.2024
End date : 30.09.2024
Project details
Scientific Abstract
ZEB1 is expressed in chemoresistant tumor cells (TCs) and cancer-associated fibroblasts (CAFs). According to our recent data, it induces replication stress (RS) which can be selectively targeted in TCs for chemo-sensitization. Furthermore, we discovered ZEB1-dependent immunosuppression in CAFs, precluding immune checkpoint therapies. As CAFs also display the ZEB1-driven RS, we now seek to target both unfavorable cell types together in an immunocompetent model to enhance therapeutic efficacy.
Involved:
Contributing FAU Organisations:
Interdisziplinäres Zentrum für Klinische Forschung (IZKF)
Lehrstuhl für Experimentelle Medizin mit dem Schwerpunkt Molekulare Pathogeneseforschung
Medizinische Fakultät
